Qiagen (QGEN) Investor update summary

Technology Overview and Differentiation

• QIAcuity digital PCR offers high sensitivity, reproducibility, and ease of use, bridging the gap between qPCR and NGS for complex sample analysis.

• The platform is fully integrated, scalable from low to high throughput, and supports multiplexing up to 12 targets per reaction, outperforming competitors in throughput and detection channels.

• Simplicity, automation, and a plate-based system make it cost-efficient and user-friendly, with a hit rate above 70% in competitive markets.

• QIAcuity fits seamlessly into the broader QIAGEN ecosystem, including GeneGlobe for assay customization, offering 10+ million predesigned assays and unlimited customization.

Market Position and Growth Strategy

• The digital PCR market is valued at $600 million, growing at over 15% CAGR, with QIAcuity capturing over 12% market share in four years.

• Revenue reached $89 million in 2025, with a target of $100 million in 2026, driven by strong differentiation and customer adoption.

• Installed base exceeds 3,200 systems, with a 75% CAGR in placements and 55% CAGR in revenue since 2020.

• Over 1,100 publications reference QIAcuity, supporting its scientific and commercial impact.

Applications and Customer Adoption

• QIAcuity is used in research, clinical diagnostics, biopharma, food safety, and environmental testing, enabling detection of low-abundance targets in complex samples.

• Clinical applications include oncology (MRD monitoring), sepsis diagnosis, and transplant monitoring, with rapid turnaround and high sensitivity.

• Customers value the platform's reproducibility, scalability, all-in-one workflow, accuracy, cost savings, and automation.

• High adoption in academia, biopharma, and clinical labs, with validated diagnostic applications and custom assay design tools.

• The transition from qPCR to dPCR is driven by the need for higher confidence and precision, especially in gene expression and monitoring applications.